MX2018012376A - Sistemas de replicón de arterivirus recombinantes y usos de estos. - Google Patents
Sistemas de replicón de arterivirus recombinantes y usos de estos.Info
- Publication number
- MX2018012376A MX2018012376A MX2018012376A MX2018012376A MX2018012376A MX 2018012376 A MX2018012376 A MX 2018012376A MX 2018012376 A MX2018012376 A MX 2018012376A MX 2018012376 A MX2018012376 A MX 2018012376A MX 2018012376 A MX2018012376 A MX 2018012376A
- Authority
- MX
- Mexico
- Prior art keywords
- viral
- expression
- heterologous polypeptides
- genome
- disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10041—Use of virus, viral particle or viral elements as a vector
- C12N2770/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción se refiere en general a sistemas de expresión a base de virus adecuados para la producción de moléculas de interés en células hospederas recombinantes. La descripción se refiere en particular a constructos de ácido nucleico, tales como vectores de expresión, que contienen un. genoma o ARN replicón de arterivirus modificado en el que al menos parte de su secuencia viral original se ha eliminado. También se incluyen en la descripción vectores de expresión a base de virus que incluyen uno o más casetes de expresión que codifican polipéptidos heterólogos. En algunas modalidades, los casetes de expresión están configurados y posicionados en ubicaciones definidas en el genoma viral para permitir la expresión de los polipéptidos heterólogos de una manera ajustable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662322149P | 2016-04-13 | 2016-04-13 | |
PCT/US2017/027249 WO2017180770A1 (en) | 2016-04-13 | 2017-04-12 | Recombinant arterivirus replicon systems and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018012376A true MX2018012376A (es) | 2019-08-01 |
Family
ID=58606592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012376A MX2018012376A (es) | 2016-04-13 | 2017-04-12 | Sistemas de replicón de arterivirus recombinantes y usos de estos. |
Country Status (7)
Country | Link |
---|---|
US (3) | US10538786B2 (es) |
EP (1) | EP3443107A1 (es) |
JP (1) | JP7250520B2 (es) |
AU (1) | AU2017249424B2 (es) |
CA (1) | CA3020426A1 (es) |
MX (1) | MX2018012376A (es) |
WO (1) | WO2017180770A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3431099B1 (en) | 2007-03-30 | 2024-01-03 | The Research Foundation for The State University of New York | Attenuated viruses useful for vaccines |
JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
JP7382230B2 (ja) | 2016-10-17 | 2023-11-16 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組み換えウイルスレプリコン系及びその使用 |
KR102655641B1 (ko) | 2016-12-05 | 2024-04-05 | 얀센 파마슈티칼즈, 인코포레이티드 | 유전자 발현을 향상시키기 위한 조성물 및 방법 |
EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
BR112020014525A2 (pt) * | 2018-01-19 | 2020-12-08 | Janssen Pharmaceuticals, Inc. | Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes |
CA3091478A1 (en) | 2018-02-17 | 2019-08-22 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
CN116134131A (zh) | 2019-12-31 | 2023-05-16 | 伊利克斯根治疗公司 | 核酸和蛋白质向细胞和组织的基于温度的瞬时递送 |
TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
AU2021241355A1 (en) | 2020-03-23 | 2022-10-13 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
JP2023531123A (ja) * | 2020-04-12 | 2023-07-21 | ノヴォスコープ アイピー リミテッド | 粒子、dna、及びrna |
WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
US20230024133A1 (en) | 2020-07-06 | 2023-01-26 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
WO2023019274A1 (en) * | 2021-08-13 | 2023-02-16 | Purdue Research Foundation | Methods and compositions for vaccination against heterosubtypic influenza viruses using an adenoviral vector leading to enhanced t cell response through autophagy |
WO2023147498A1 (en) * | 2022-01-27 | 2023-08-03 | Replicate Bioscience, Inc. | Methods for generating functional self-replicating rna molecules |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
EP0091539B2 (en) | 1982-03-31 | 1996-11-27 | Ajinomoto Co., Inc. | Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells |
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4892743A (en) | 1983-12-21 | 1990-01-09 | Schering Corporation | Novel hybrid interferon species |
WO1985002862A1 (en) | 1983-12-23 | 1985-07-04 | Monash University | PRODUCTION OF HUMAN INTERFERON-alpha |
AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
PT92479A (pt) | 1988-12-01 | 1990-06-29 | Univ North Carolina | Processo de preparacao de genes recombinantes e suas proteinas de codificacao |
US5225337A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
US5246921A (en) | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
US5780036A (en) | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
ATE227118T1 (de) | 1993-08-02 | 2002-11-15 | Scripps Research Inst | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus |
SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
DE19712889A1 (de) | 1997-03-27 | 1998-10-01 | Bosch Gmbh Robert | Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
CA2285056C (en) | 1997-04-03 | 2004-12-14 | Iacob Mathiesen | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
US5873849A (en) | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
US6117660A (en) | 1997-06-10 | 2000-09-12 | Cytopulse Sciences, Inc. | Method and apparatus for treating materials with electrical fields having varying orientations |
IL133710A0 (en) | 1997-06-30 | 2001-04-30 | Rhone Poulence Rorer S A | Improved method for transferring nucleic acid into the striped muscle and combination thereof |
US5958060A (en) | 1998-01-02 | 1999-09-28 | General Electric Company | Method and apparatus for clock control and synchronization |
WO2000002621A1 (en) | 1998-07-13 | 2000-01-20 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6319901B1 (en) | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
US20040213805A1 (en) | 1999-10-12 | 2004-10-28 | Verheije Monique Helene | Deletions in arterivirus replicons |
AU2001290642A1 (en) | 2000-09-07 | 2002-03-22 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
US6538922B1 (en) | 2000-09-27 | 2003-03-25 | Sandisk Corporation | Writable tracking cells |
NZ524661A (en) | 2000-11-23 | 2005-03-24 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
WO2002061113A2 (en) | 2001-02-01 | 2002-08-08 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
ATE354260T1 (de) | 2001-07-19 | 2007-03-15 | Ericsson Telefon Ab L M | Verfahren und vorrichtung für die lösung der nummernübertragbarkeit am ursprungsort |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
US6943015B2 (en) | 2002-12-12 | 2005-09-13 | Ilya Frolov | Large scale production of packaged alphavirus replicons |
EP1651666B1 (en) | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
US8080255B2 (en) * | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
US20050070700A1 (en) | 2003-09-30 | 2005-03-31 | Matthias Giese | Equine arteritis virus vaccine |
CN102886101B (zh) | 2004-03-08 | 2015-10-28 | 艾科医疗系统公司 | 改进的治疗剂电介导输送设备 |
US8859198B2 (en) | 2006-06-06 | 2014-10-14 | Abl Sa | Detection and use of antiviral resistance mutations |
WO2008115199A2 (en) | 2006-08-18 | 2008-09-25 | The University Of North Carolina At Chapel Hill | Chimeric virus vaccines |
WO2008048632A1 (en) | 2006-10-17 | 2008-04-24 | Vgx Pharmaceuticals, Inc. | Electroporation devices and methods of using same for electroporation of cells in mammals |
US20090018031A1 (en) | 2006-12-07 | 2009-01-15 | Switchgear Genomics | Transcriptional regulatory elements of biological pathways tools, and methods |
KR100836745B1 (ko) | 2007-01-31 | 2008-06-10 | (주)두비엘 | Hbv 백신 및 그의 제조 방법 |
ES2588906T3 (es) | 2007-06-21 | 2016-11-07 | Alphavax, Inc. | Casetes sin promotor para la expresión de proteínas estructurales de alfavirus |
JP4457135B2 (ja) | 2007-09-26 | 2010-04-28 | 株式会社日立ハイテクノロジーズ | 液体クロマトグラフ分析装置及び試料導入装置 |
WO2009056535A2 (en) | 2007-10-29 | 2009-05-07 | Genimmune N.V. | Methods and kits for inducing a ctl response using a prime boost regimen |
WO2011015656A2 (en) | 2009-08-07 | 2011-02-10 | Transgene Sa | Composition for treating hbv infection |
EP2590670B1 (en) | 2010-07-06 | 2017-08-23 | GlaxoSmithKline Biologicals SA | Methods of raising an immune response by delivery of rna |
EP2655621B1 (en) | 2010-12-20 | 2018-05-23 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
PT2672992T (pt) | 2011-02-11 | 2020-07-27 | Univ Pennsylvania | Molécula de ácidos nucleicos codificando proteína nuclear do vírus da hepatite b e vacina compreendendo a mesma |
TWI623618B (zh) | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Hbv聚合酶突變體 |
US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
WO2014170493A2 (en) | 2013-04-19 | 2014-10-23 | Novartis Ag | Alphavirus vector |
CA2915730A1 (en) | 2013-08-21 | 2015-02-26 | Karl-Josef Kallen | A combination rsv/influenza a vaccine |
WO2016020538A1 (en) | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
CN106794263A (zh) | 2014-10-01 | 2017-05-31 | 宾夕法尼亚大学理事会 | 具有抗原和作为佐剂的白细胞介素‑21的疫苗 |
KR20170134642A (ko) | 2015-04-08 | 2017-12-06 | 노파르티스 아게 | Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법 |
CN107810009A (zh) | 2015-05-15 | 2018-03-16 | 库瑞瓦格股份公司 | 涉及施用至少一种mRNA构建体的初免‑加强方案 |
WO2017024000A1 (en) | 2015-08-03 | 2017-02-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use |
MX2018011742A (es) | 2016-03-28 | 2019-02-14 | Ichor Medical Systems Inc | Metodo y aparato para suministro de agentes terapeuticos. |
CN109414496B (zh) | 2016-04-06 | 2024-01-26 | 华盛顿大学 | 用于乙型肝炎病毒(hbv)的使用hbv核心抗原的治疗性疫苗 |
JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
JP7382230B2 (ja) | 2016-10-17 | 2023-11-16 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組み換えウイルスレプリコン系及びその使用 |
KR102655641B1 (ko) | 2016-12-05 | 2024-04-05 | 얀센 파마슈티칼즈, 인코포레이티드 | 유전자 발현을 향상시키기 위한 조성물 및 방법 |
EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
-
2017
- 2017-04-12 JP JP2018553420A patent/JP7250520B2/ja active Active
- 2017-04-12 US US15/486,131 patent/US10538786B2/en active Active
- 2017-04-12 EP EP17718781.2A patent/EP3443107A1/en active Pending
- 2017-04-12 CA CA3020426A patent/CA3020426A1/en active Pending
- 2017-04-12 MX MX2018012376A patent/MX2018012376A/es unknown
- 2017-04-12 AU AU2017249424A patent/AU2017249424B2/en active Active
- 2017-04-12 WO PCT/US2017/027249 patent/WO2017180770A1/en active Application Filing
-
2019
- 2019-12-04 US US16/703,359 patent/US11555205B2/en active Active
-
2023
- 2023-01-13 US US18/154,278 patent/US20230227850A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200123573A1 (en) | 2020-04-23 |
JP7250520B2 (ja) | 2023-04-03 |
JP2019511232A (ja) | 2019-04-25 |
US20170314043A1 (en) | 2017-11-02 |
AU2017249424B2 (en) | 2023-08-24 |
WO2017180770A1 (en) | 2017-10-19 |
US20230227850A1 (en) | 2023-07-20 |
EP3443107A1 (en) | 2019-02-20 |
CA3020426A1 (en) | 2017-10-19 |
US11555205B2 (en) | 2023-01-17 |
US10538786B2 (en) | 2020-01-21 |
AU2017249424A1 (en) | 2018-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018012376A (es) | Sistemas de replicón de arterivirus recombinantes y usos de estos. | |
MX2019004499A (es) | Sistemas de replicón de virus recombinante y usos de estos. | |
SA517381912B1 (ar) | "عناصر تنظيمية معدلة بعد الانتساخ لعلاج الالتهاب الكبدي pre | |
MX2016010649A (es) | Vector de virus adeno-asociado. | |
MX2019003674A (es) | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. | |
SA517390590B1 (ar) | Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة | |
MY192561A (en) | Taurine supplemented cell culture medium and methods of use | |
WO2015200920A8 (en) | Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof | |
CA3033327A1 (en) | Programmable cas9-recombinase fusion proteins and uses thereof | |
EP3741849A3 (en) | Protease variants and polynucleotides encoding same | |
MX2017014125A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
UA120923C2 (uk) | Молекула нуклеїнової кислоти, яка кодує капсидний протеїн aav5 | |
EA201792236A1 (ru) | Получение увеличенных в размере векторов на основе аденоассоциированного вируса | |
MX2020005282A (es) | Vector para la produccion de particulas aav. | |
UA120917C2 (uk) | Химерний білок фактора viii та його застосування | |
MX2018007485A (es) | Variantes de enzimas y polinucleotidos que las codifican. | |
WO2016022377A3 (en) | Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen | |
MX2016008258A (es) | Celulas eucariotas novedosas y metodos para la expresion recombinante de un producto de interes. | |
MX2018000845A (es) | Vector vírico orf recombinante. | |
MX356162B (es) | Sistema de expresion y secrecion. | |
MX2019000805A (es) | Variantes de serinproteasa y polinucleotidos que las codifican. | |
EP4316500A3 (en) | Bio-production of lentiviral vectors | |
MY187130A (en) | Variants of gal2 transporter and their uses | |
PH12018502656A1 (en) | Engineered beta-glucosidases and glycosylation methods | |
WO2018060368A3 (en) | COMPOSITIONS AND METHODS FOR ENHANCING STABILITY OF TRANSGENES IN POXVIRUSES |